Strategy to reduce adverse health outcomes in subjects highly vulnerable to COVID-19: results from a population-based study in Northern Italy

Antonio Giampiero Russo,1 Marino Faccini,2 Walter Bergamaschi,3 Antonio Riusi1

ABSTRACT

Objectives This study describes a new strategy to reduce the impact of COVID-19 on the elderly and other clinically vulnerable subjects, where general practitioners (GPs) play an active role in managing high-risk patients, reducing adverse health outcomes.

Design Retrospective cohort study.

Setting Population-based study including subjects resident in the province of Milan and Lodi.

Participants 127 735 residents older than 70 years, with specific chronic conditions.

Interventions We developed a predictive algorithm for overall mortality risk based on demographic and clinical characteristics. All residents older than 70 years were classified as being at low or high risk of death from COVID-19 infection according to the algorithm. The high-risk group was assigned to their GPs for telephone triage and consultation. The high-risk cohort was divided into two groups based on GP intervention: patients who were not contacted and patients who were contacted by their GPs.

Outcome measures Overall mortality, COVID-19 morbidity and hospitalisation.

Results Patients with increased risk of death from COVID-19 were 127 735; 495 669 patients were not at high risk and were not included in the intervention. Out of the high-risk subjects, 79 110 were included but not contacted by their GPs, while 48 625 high-risk subjects were included and contacted. Overall mortality, morbidity and hospitalisation was higher in high-risk patients compared with low-risk patients. High-risk patients contacted by their GPs had a 50% risk reduction in COVID-19 mortality, and a 70% risk reduction in morbidity and hospitalisation for COVID-19 compared with non-contacted patients.

Conclusions The study showed that, during the COVID-19 outbreak, involvement of GPs and changes in care management of high-risk groups produced a significant reduction in all adverse health outcomes.

INTRODUCTION

On 19 February 2020, the first case of COVID-19 was identified in Italy, in the province of Milan. Previously, the epidemic had been confined to China, with several restrictions active at the national and international levels. Since large Chinese communities are present in many Italian metropolitan areas, the first cases were expected in these areas. Instead, the first case occurred in a non-metropolitan area, in the municipality of Codogno, which has just over 15 000 inhabitants. The first case had an initial non-specific set of symptoms that delayed the identification of COVID-19. After the first case, 46 close contacts, including healthcare staff of the Codogno hospital, were infected, effectively starting the Italian phase of the COVID-19 pandemic.1

On 23 February, 50 000 residents were ordered into isolation in the municipalities surrounding Codogno; despite this, COVID-19 spread to the provinces of Cremona, Mantua, Bergamo and Brescia. Pursuing the same strategy as the Chinese government, a national lockdown was ordered on 8 March.2,3

Strengths and limitations of this study

- This is the first population-based study that includes all people resident in the largest metropolitan area of Northern Italy and focuses on patients at high-risk for COVID-19 mortality.
- We defined a highly discriminating algorithm model, based on administrative health data, to identify groups experiencing high mortality.
- The study highlights how the involvement of general practitioners and implementation of changes in the care management of high-risk groups produce a significant reduction in all adverse health outcomes.
- The multiprofessional intervention involved patients, general practitioners, epidemiologists, IT experts and politicians and entailed a rapid data collection during a rapidly evolving pandemic emergency.
- As this pragmatic study in a COVID-19 hot spot is analysed retrospectively and not randomised, it does not guarantee protection from residual confounding due to unmeasured variables.
Without effective prevention or treatment measures, the main strategy to control COVID-19 focused on different community-based intervention models. To address virus transmission, governments worldwide faced a choice between mitigation or suppression strategies. Some governments opted for suppression, as more than 40 countries or regions worldwide enacted population lockdowns.6 7 Other governments aimed for mitigation, trying to slow rather than stop the spread of the virus.8

Each country developed specific approaches based on mixing surveillance and testing strategies, community and distancing measures and healthcare reforms to increase intensive care capacity and reduce all other non-essential medical activities.9 Although less than 1% of patients with COVID-19 die, the sheer number of infections resulted in increased hospital admissions, and most patients needed intensive care. Consequently, hospitals became overburdened, and deaths increased.10

The majority of patients hospitalised with COVID-19 were older and had underlying medical conditions, with increased age being associated with clinical severity, including case fatality. The most frequent comorbidities reported in Chinese patients with COVID-19 were hypertension (20%), diabetes (10%), cardiovascular disease (8%) and respiratory system disease (2%).11 12

In the US population, common comorbidities were hypertension (60%), obesity (40%) and diabetes (34%).13 14

On 1 March, with data released at the regional level providing a clear idea of the heavy human, social and economic losses, we observed the progress of the epidemic without any tool other than our knowledge as public health epidemiologists. Was it possible that epidemiologists, during this pandemic event, could only observe the progress of events and could take no other action based on their experience?

The world stopped, cities were deserted and people were locked in their homes. Under widespread lockdown conditions, we studied a rapid, although rudimentary, predictive model to identify the characteristics of the elderly population dying from COVID-19. Our main idea was to generate a rapid, simple information system capable of incorporating the cohort of subjects more susceptible to dying into a web application that would allow general practitioners (GPs) to operate actively, in particular since clinics were closed due to the restrictive measures implemented. With an extensive effort, even considering the extremely short time available due to the speed of contagion, this system provided GPs of Milan’s Agency for Health Protection (Agenzia per la Tutela della Salute (ATS)) with a tool to protect, treat and supervise those who needed it most at that time. All that was needed was a staunch resolution to transform an idea into a real action plan in the midst of a public health emergency; this could be done only by the general manager of the ATS.

The vivid portrayal previously is necessary to introduce the concept that most COVID-19 patients are asymptomatic, and infection becomes clinically relevant most frequently in elderly patients with comorbidities. The national strategic plan did not specify, at the population level, all surveillance actions needed to trace the most at-risk patients and include them in a system to limit adverse health and social effects; only general recommendations were issued instead.

This work aims to present the results of a population-based intervention on the elderly and COVID-19 vulnerable population. The intervention used a mortality prediction model based on early data that implements a web-based information system and a concerted effort by GPs. This multidisciplinary action, coordinated by the Epidemiology Unit of Milan’s ATS and performed by GPs in the provinces of Lodi and Milan, represents a new consensus model to reduce mortality rates during public health emergencies.

MATERIALS AND METHODS

Information system

From the beginning of the outbreak, all tracing activities were included in a newly dedicated web-based platform called Milano COV, which allows for identification of cases and related contacts. The ATS health system contains data on all laboratory-confirmed cases of COVID-19. Confirmation of COVID-19 infection was provided by reverse transcription PCR (RT-PCR) on nasopharyngeal swabs performed in 12 regional laboratories.

The system includes only laboratory-confirmed cases of COVID-19 infection, irrespective of clinical symptoms. Contacts are defined as all individuals associated with some range of activity of the case and who may have similar exposures as the case. Contacts can include household members, other family members, visitors, neighbours, colleagues, teachers, classmates, coworkers, social or health workers and members of social groups. The epidemiological investigation among cases and contacts was set to provide descriptions of the clinical presentation of COVID-19 infection and course of associated diseases, serial interval of COVID-19 infection, symptomatic proportion of COVID-19 cases and identification of possible transmission routes.

In the first week of March, the web portal was available to all GPs, allowing them to identify cases and close contacts and conduct telephone follow-up with non-hospitalised cases. It also allowed GPs to communicate with any symptomatic cases and their close contacts asking for therapeutic indications. Furthermore, at the time, GPs also gave indication that quarantine should be maintained as if they were confirmed cases/close contacts.

During the outbreak, mayors were to be sent all data relating to identified cases and contacts. A list of cases and close contacts was provided, for each municipality, in order to ensure that containment measures were followed and verify the need for any social support (eg, grocery shopping and medications). The prefectures in Milan and Lodi used the same information to enforce the
restrictive measures provided for by law. The same informational structure also allowed for tracing case evolution and follow-up of cases until PCR negativisation and the end of quarantine for close contacts. Additionally, GPs had the option of adding exclusively symptomatic cases and their close contacts to expand the outbreak reporting system. This integrated platform (ATS Milano COR) contained personal data and detailed information on both cases and contacts, identified through epidemiological investigations, and GP-reported symptomatic cases and contacts, available to 193 municipal administrations, for specific population interventions, and to the prefectures of Milan and Lodi, for all containment and support measures provided for by specific legislation.

For cases and contacts reported by GPs, in addition to starting surveillance based on active tracing in the general population, massive SMS systems were activated both to strengthen the indications for segregation and send links with information on how to quarantine at home.

Patient and public involvement
Patients who took part in the GP intervention were involved in the study, as they were contacted by telephone and received specific indications from their GPs. Results will be presented to the GPs of Milan’s ATS after formal acceptance and publishing by a peer-reviewed journal.

Predictive algorithm for overall mortality risk
In the first fortnight of March, available data were used to develop a predictive algorithm for overall mortality risk. Predictors were chosen based on the magnitude of the association and reproducibility of the results that emerged each day (not for significance), as well as clinical relevance, by using logistic regression analysis. The final models predicting mortality risk in COVID-19 cases included neurological disorders (dementia, Alzheimer’s disease and Parkinson’s disease), heart failure, ischaemic cardiomyopathy, valvular disease, renal failure (including dialysis) and cancer diagnosed in the last 2 years.

Classification of high-risk subjects
Only patients over the age of 70 years and under the care of GPs of Milan’s ATS were included. All residents of nursing homes, extended care units and long-term care facilities were excluded. All subjects classified as at high risk of death were included in the prospective intervention. Patients in the cohort were distributed based on the final models predicting mortality risk in COVID-19 cases stratified into patients not included in high-risk cohort (G1), included but not contacted by GPs (G2) and included and contacted by GPs (G3).

Outcome variables
Overall mortality
Vital status was derived from the early notification system of the ATS of Milan, set up at the beginning of the epidemic, in which deaths are communicated from the civil registry of each municipality to the ATS, manually entered in the Health Service Register, and directly from the GPs’ and mayors’ offices for patients already in the COVID-19 database through the web-based information system.

COVID-19 morbidity
Morbidity rates of confirmed COVID-19 cases from the high-risk cohort were identified using the registry of molecular RT-PCR diagnostic testing results based on nasal swabs.

COVID-19 hospitalisation
Hospitalised confirmed COVID-19 cases were identified using a specific regional flow. For all confirmed cases, the information system provides the date and location of hospitalisation and the date of discharge.

Statistical analysis
To evaluate the beneficial effect of the developed classification, the population of patients aged over 70 years was stratified into patients not included in high-risk surveillance (G1), included but not contacted by GPs (G2) and included and contacted by GPs (G3).

Mortality, morbidity and hospitalisation events were identified from the date on which the system started up (13 March) to the date on which mortality of the general population went back to its pre-epidemic expected value (31 May). All events after the end of the study observation period were censored and considered non-events. Both multivariate logistic analysis and proportional hazards models were used to estimate ORs and HRs, and 95% CIs were used to assess the relationships between mortality, morbidity and hospitalisation.

Separate models were fitted to the data comparing G2+G3 together versus G1, G2 versus G1 and G3 versus G1, and, finally, G3 versus G2. Individual-level comorbidities data were derived using the administrative chronic disease database of the ATS of Milan, according to the algorithms specified in Regional Act X/616418 and X/765519 of 2017. The number of different pharmacological treatments was defined on the basis of the seven-digit ATC code and subdivided into a polytherapy group (more than five treatments but less than 10) and a hypertherapy group (more than 10 tracers), using those who used less than five different treatments as a reference.

Overall systemic health was determined using the Charlson Comorbidity Index (CCI) score, which assigns patients a score between 0 and 6, based on the likelihood of mortality secondary to age and the presence or
absence of selected systemic diseases. The CCI includes myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, cirrhosis, hepatic failure, immunosuppression, diabetes mellitus with or without complications, haemiplegia or paraplegia, chronic renal disease, malignant neoplasms, multiple myeloma or leukaemia, lymphomas, metastatic solid tumours and AIDS.15

For logistic regression analysis, the model prediction was calculated using Harrell’s C-statistic: up to 0.5 (as good as a random guess), 0.7 to 0.8 (acceptable), 0.8 to 0.9 (excellent), and 0.9 to 1.0 (outstanding prediction).16

The Cox proportional hazard assumption was checked for each covariate using Schoenfeld residuals tests and graphically using a log-log plot of survival.

All statistical analyses were performed using SAS V9.4 for Windows (SAS Institute, Inc, Cary, North Carolina, USA).

RESULTS

Predictive algorithm for overall mortality risk

On 13 March, there were 2981 confirmed cases of COVID-19. Of these, 435 (14%) died before 15 March 2020. A total of 1004 cases were 70 years and older, and of these, 392 (28%) had died. On the date the prediction model was implemented, the C-index was 0.81.

Cohorts

On 20 April 2020, 623 404 patients aged over 70 years were identified. Of these, 127 735 (20.5%) had comorbid conditions that increased their risk of death from COVID-19. At the time of cohort inclusion, there were 2047 GPs in the ATS of Milan; 1454 (71%) logged on to ATS Milano COR and 1132 (55%) contacted more than five patients via telephone (min–max: 5–153, mean: 43, median: 41), for a total of 48 624 patients (38%). The mean age of patients contacted by GPs was 59 versus 61 for patients not contacted; 59% of complying GPs worked in the city of Milan, while 48% worked in another province of Milan and Lodi. Sociodemographic characteristics of the patients belonging to the two groups of GPs were not different: female gender (51% not contacted vs 53% contacted), patients older than 70 years (19% vs 19%) and foreigners (14% vs 14%).

By using all the clinical conditions included in the algorithm, 127 735 patients out of 623 404 (20.5%) over the age of 70 years were classified as at high mortality risk for COVID-19. The cohort of patients older than 70 years was subdivided into three different cohorts: (G1) without any specific risk conditions (495 669; 79%); (G2) with risk conditions but not contacted by GPs (79 110; 13%); and (G3) with risk conditions in contact with GPs (48 625; 8%). Table 1 shows the baseline characteristics of the different cohorts: included and contacted patients were very close to non-contacted patients in age and gender distribution; both were older, with a higher proportion of women.

The cohort with risk conditions and the cohort without the prevalence of diseases, polytherapy and CCI are different by design. Instead, the risk condition cohort showed a very similar distribution of clinical characteristics between contacted and non-contacted patients, with no clear selection between the two groups.

Comparison

Table 1 reports the estimates provided by the full logistic and Cox models; all predictors presented were included simultaneously in a unique model.

Mortality risk was significantly higher for older people (HR=7.53; OR=10.98), patients who received more than 10 different treatments (HR=8.38; OR=10.27), had chronic gastrointestinal diseases (inflammatory bowel disease (IBD) and cirrhosis) (HR=32.69; OR=66.57), chronic obstructive pulmonary disease (COPD, HR=34.64; OR=53.97), renal failure (HR=9.31; OR=50.29), diabetes (HR=37.64; OR=93.23), cardiovascular disease (HR=59.98; OR=374.8), neoplasm (HR=115.9; OR=39.88), autoimmune diseases (HR=32.16; OR=36.5), highest CCI score (HR=13.21; OR=48.32) and influenza vaccination (HR=1.08; OR=1.09). Female gender (HR=0.40; OR=0.32) and pneumococcal vaccination (HR=0.79; OR=0.71) were inversely associated with mortality risk. The C-index derived from the logistic model was very high, with a value of 0.93, indicating an outstanding prediction of mortality.

The risk of having a positive RT-PCR test, based on nasal swabs, was significantly higher in older people (HR=2.37; OR=2.32, 90+ years), patients who received more than 10 different treatments (HR=3.14; OR=3.04), had COPD (HR=1.67; OR=1.62), renal failure (HR=1.73; OR=1.66), diabetes (HR=1.69; OR=1.64), cardiovascular disease (HR=2.15; OR=2.07), neoplasm (HR=2.02; OR=1.95), autoimmune diseases (HR=1.89; OR=1.86) and highest CCI score (HR=2.17; OR=2.05). The risk was inversely associated only with female gender (OR=0.53; HR=0.54). The C-index derived from the logistic model was 0.70, indicating an acceptable prediction of COVID-19 infection.

Risk of hospitalisation for COVID-19 was significantly higher for older people (HR=1.66; OR=1.61, 90+ years), patients who received more than ten different treatments (HR=3.64; OR=3.51), had COPD (HR=1.56; OR=1.50), renal failure (HR=1.72; OR=1.65), diabetes (HR=1.70; OR=1.65), cardiovascular disease (HR=2.33; OR=2.24), neoplasm (HR=2.06; OR=1.99), autoimmune diseases (HR=1.90; OR=1.87) and highest CCI score (HR=2.05; OR=1.92). Hospitalisation risk was inversely associated with female gender (HR=0.43; OR=0.44) and influenza vaccination (HR=0.89; OR=0.89). The C-index derived from the logistic model was 0.68, indicating an acceptable prediction of hospitalisation for COVID-19 infection.
### Table 1: Distribution of different population sets and HRs from Cox models and ORs from logistic models and corresponding 95% CIs for several outcomes

| Age class (years) | Population not included | Included but not contacted | Included and contacted | Total | Overall mortality | COVID-19 morbidity | COVID-19 hospitalisation |
|-------------------|-------------------------|---------------------------|-----------------------|-------|------------------|---------------------|-------------------------|
|                   | N (%)                   | N (%)                     | N (%)                 | N    | HR (95% CI)      | OR (95% CI)        | HR (95% CI)            |
| 70–74             | 167 516 (33.8)          | 16 049 (20.29)            | 9370 (19.27)          | 192 935 | 1                 | 1                   | 1                       |
| 75–79             | 125 115 (25.24)         | 17 347 (21.93)            | 12 778 (26.28)        | 142 833 | 2.26 (2.18 to 2.36) | 1.72 (1.61 to 1.84) | 1.28 (1.19 to 1.39)    |
| 80–84             | 108 993 (21.99)         | 20 564 (25.99)            | 12 778 (26.28)        | 142 833 | 2.36 (2.34 to 2.40) | 1.72 (1.61 to 1.84) | 1.28 (1.19 to 1.39)    |
| 85–89             | 60 515 (12.21)          | 15 646 (19.78)            | 9863 (20.28)          | 95 184 | 4.20 (3.74 to 4.55) | 2.51 (2.15 to 2.90) | 1.60 (1.28 to 2.01)    |
| 90+               | 33 530 (6.76)           | 15 646 (19.78)            | 9863 (20.28)          | 141 175 | 7.53 (6.95 to 8.15) | 10.98 (9.05 to 12.00) | 1.27 (1.17 to 1.38)    |

#### Gender

| Gender            | Population not included | Included but not contacted | Included and contacted | Total | HR (95% CI)      | OR (95% CI) |
|-------------------|-------------------------|---------------------------|-----------------------|-------|------------------|-------------|
|                   | N (%)                   | N (%)                     | N (%)                 | N    | HR (95% CI)      | OR (95% CI) |
| Males             | 199 309 (40.21)         | 38 732 (48.96)            | 23 808 (48.96)        | 261 849 | 1                 | 1            |
| Females           | 296 360 (59.79)         | 40 378 (51.04)            | 24 817 (51.04)        | 361 555 | 0.40 (0.38 to 0.42) | 0.32 (0.31 to 0.34) |

#### Polytherapy

| Polytherapy       | Population not included | Included but not contacted | Included and contacted | Total | HR (95% CI)      | OR (95% CI) |
|-------------------|-------------------------|---------------------------|-----------------------|-------|------------------|-------------|
| No polytherapy/  | 238 072 (48.03)         | 9579 (12.11)              | 4758 (9.79)           | 252 409 | 1                 | 1            |
| no hypertherapy   |                          |                           |                       |       |                  |             |
| Hypertherapy      | 68 150 (13.75)          | 37 802 (47.78)            | 24 829 (51.04)        | 130 781 | 8.38 (7.84 to 8.96) | 10.27 (9.57 to 11.02) |

#### IBD and cirrhosis

| IBD and cirrhosis| Population not included | Included but not contacted | Included and contacted | Total | HR (95% CI)      | OR (95% CI) |
|------------------|-------------------------|---------------------------|-----------------------|-------|------------------|-------------|
| No               | 492 858 (99.43)         | 76 125 (96.23)            | 46 724 (96.09)        | 615 707 | 1                 | 1            |
| Yes              | 2811 (0.57)             | 2985 (3.77)               | 1901 (3.91)           | 7976 | 32.69 (10.54 to 101.48) | 66.57 (19.92 to 222.48) |

#### COPD

| COPD             | Population not included | Included but not contacted | Included and contacted | Total | HR (95% CI)      | OR (95% CI) |
|------------------|-------------------------|---------------------------|-----------------------|-------|------------------|-------------|
| No               | 472 949 (95.42)         | 63 154 (79.83)            | 38 018 (78.19)        | 574 121 | 1                 | 1            |
| Yes              | 22 720 (4.58)           | 15 956 (20.17)            | 10 607 (21.81)        | 49 283 | 34.64 (24.81 to 48.36) | 53.97 (38.26 to 76.12) |

#### Renal failure

| Renal failure    | Population not included | Included but not contacted | Included and contacted | Total | HR (95% CI)      | OR (95% CI) |
|------------------|-------------------------|---------------------------|-----------------------|-------|------------------|-------------|
| No               | 490 711 (99)            | 69 669 (88.07)            | 42 293 (86.98)        | 60 267 | 1                 | 1            |
| Yes              | 4956 (1)                | 9441 (11.93)              | 6332 (13.02)          | 20 731 | 9.31 (6.40 to 13.54) | 50.29 (37.54 to 67.37) |

#### Diabetes

| Diabetes         | Population not included | Included but not contacted | Included and contacted | Total | HR (95% CI)      | OR (95% CI) |
|------------------|-------------------------|---------------------------|-----------------------|-------|------------------|-------------|
| No               | 426 120 (85.97)         | 60 642 (76.66)            | 36 973 (76.04)        | 523 735 | 1                 | 1            |

Continued
| Age class (years) | Total | Overall mortality | COVID-19 morbidity | COVID-19 hospitalisation |
|------------------|-------|-------------------|--------------------|--------------------------|
|                  | N (%) | HR (95% CI)       | OR (95% CI)        | HR (95% CI)              |
|                   |       |                   |                    |                          |
| *Yes*            | 99669 | 37.64 (28.24 to 50.16) | 93.23 (76.82 to 113.15) | 1.69 (1.56 to 1.82)      |
| *Cardiovascular* |       |                   |                    |                          |
| No               | 431214 | 14.03 | 18878 (23.86) | 38667 (79.52) | 59.98 (49.76 to 72.31) | 374.8 (275.5 to 509.9) | 2.15 (2.02 to 2.29) |
| Yes              |       |                   |                    |                          |
| Neoplasms        | 497926 | 1882 | 60232 (76.14) | 11652 (23.96) | 115.9 (87.4 to 153.6) | 39.88 (20.56 to 77.34) | 2.02 (1.86 to 2.19) |
| No               | 405885 | 1811 | 57383 (72.54) | 34658 (71.28) | 32.16 (16.72 to 61.85) | 36.5 (19.0 to 70.2) | 1.89 (1.59 to 2.25) |
| Yes              |       |                   |                    |                          |
| Autoimmune diseases | 125478 | 1811 | 21727 (27.46) | 13967 (28.72) | 115.9 (87.4 to 153.6) | 39.88 (20.56 to 77.34) | 2.02 (1.86 to 2.19) |
| No               | 475526 | 9678 | 60557 (76.55) | 37173 (76.45) | 37.64 (28.24 to 50.16) | 93.23 (76.82 to 113.15) | 1.69 (1.56 to 1.82) |
| Yes              |       |                   |                    |                          |
| Charlson index   | 573256 | 9594 | 60557 (76.55) | 37173 (76.45) | 37.64 (28.24 to 50.16) | 93.23 (76.82 to 113.15) | 1.69 (1.56 to 1.82) |
| 0                |       |                   |                    |                          |
| 1                | 16739 | 7.88 (7.24 to 8.58) | 14.11 (12.50 to 15.94) | 3.21 (2.89 to 3.56)      |
| 2                | 6610  | 8.35 (7.46 to 9.35) | 20.12 (16.67 to 24.28) | 3.82 (3.27 to 4.47)      |
| 3                | 2715  | 7.98 (6.81 to 9.35) | 25.87 (19.14 to 34.96) | 3.76 (2.98 to 4.74)      |
| 4                | 726   | 12.50 (9.33 to 16.75) | 60.20 (30.39 to 119.23) | 5.59 (3.82 to 8.17)      |
| 5+               | 23358 | 13.21 (12.22 to 14.30) | 48.32 (41.80 to 55.86) | 2.17 (1.91 to 2.46)      |
| Influenza vaccination |       |                   |                    |                          |
| No               | 307160 | 1.15 | 6886 (8.72) | 4121 (8.48) | 7.88 (7.24 to 8.58) | 14.11 (12.50 to 15.94) | 3.21 (2.89 to 3.56) |
| Yes              |       |                   |                    |                          |
| Pneumococcal vaccination |       |                   |                    |                          |
| No               | 580917 | 0.27 | 3246 (4.1) | 2019 (4.15) | 8.35 (7.46 to 9.35) | 20.12 (16.67 to 24.28) | 3.82 (3.27 to 4.47) |
| Yes              |       |                   |                    |                          |
| |
Outcomes

Overall mortality

Among the 623,404 patients included in the population-based study, 7,831 died (1.26%); overall mortality was 0.83% in the low-risk population (G1, 41,25 events), 3.87% in the high-risk population not contacted by GPs (G2, 3065 events) and 1.32% in the high-risk population contacted by GPs (G3, 641 events) (table 2).

The high-risk population (G2+G3) had a six to eight times increase in significant mortality risk, compared with the average-risk reference population (HR=6.24; OR=8.30), indicating good performance of the selection criteria identified. If the reference population was compared with the high-risk population subdivided based on GP intervention, the mortality risk for non-contacted patients was 8–11 times higher (HR=7.86; OR=11.21); conversely, the contacted high-risk population had a three-fold risk increase (HR=3.14; OR=3.89). Comparing high-risk patients, contacted patients had half the mortality risk of non-contacted patients (HR=0.59; OR=0.33).

COVID-19 morbidity

Out of 61,666 patients with a positive RT-PCR test, based on nasal swabs, 0.79% were in the low-risk population (G1, 3,889 events), 2.46% in the high-risk population not contacted by GPs (G2, 1,942 events) and 0.69% in the high-risk population contacted by GPs (G3, 335 events). The high-risk population showed a threefold risk increase, with respect to the reference population. When the reference population was compared with the two high-risk populations, the risks were very different: the non-contacted patients had a 1.4–3.7-fold risk increase, while contacted patients had the same risk as the reference population. When contacted and non-contacted patients were compared, the reduction in risk increase was 70% (HR=0.29; OR=0.30).

COVID-19 hospitalisation

A total of 51,89 patients were hospitalised: 0.67% in the low-risk population (G1, 3,343 events), 1.96% in the high-risk population not contacted by GPs (G2, 1,548 events) and 0.61% in the high-risk population contacted by GPs (G3, 298 events). The high-risk population had a threefold risk increase compared with the reference population.

The risk of hospitalisation for COVID-19 did not differ between the reference and contacted population; instead, the non-contacted population had a threefold increase in risk. When contacted and non-contacted patients were compared, risk was shown to decrease by approximately 70% (HR=0.32; OR=0.34).

DISCUSSION

This study aimed to investigate whether patients with a specific predictive COVID-19 mortality profile show reduced mortality rates if they are under the care of GPs using a proactive and integrated model. The differences
between the active GP intervention group and the untreated group are striking and confirmed a functioning information system, particularly needed in future waves.

This study has two significant results. The first is the identification of a selection model of the population at risk based on where mortality, morbidity and hospitalisation events occurred. The second is that the group of patients who GPs engaged in multidisciplinary interaction showed a 50% reduction in mortality and in infection and hospitalisation risk compared with non-contacted patients.

The epidemiology of infectious diseases originated in 1854, during the London cholera epidemic, when the epidemiologist John Snow realised that it was possible to begin to understand the mechanisms of disease spread in the population, showing how great a role identification of new cases of infection in the population plays in maintaining population health. Since then, there have been many epidemics among various populations, and while a high price has been paid globally, there has also been an evolution in the methods for epidemic containment. The last major pandemic was the Spanish influenza epidemic over 100 years ago, which fell on a world devastated by a world war and a recession, and caused 50 million deaths in the absolute impossibility of any containment action.

According to WHO guidelines, the containment of an epidemic is based on the identification of epidemic clusters and their isolation, which allows, in particular situations, to identify and isolate their sources. Epidemiological investigation consists in the identification of a case and all potential close contacts and includes a targeted prescription of quarantine and information activity aimed at isolating the cluster. If the epidemic develops in a low-density or rural area, operators who conduct personal interviews can contact the case. For urban or densely inhabited areas, case identification is based on diagnostic testing. Therefore, cases are contacted a few days after the collection of biological material. Generally, this contact takes place in the form of telephone calls made by trained professionals who detect a range of structured information, including business contacts and identification of close contacts. However, if this modality can guarantee containment results for epidemic clusters of meningitis or legionella, dealing with a pandemic with these tools now becomes impractical due to the high number of cases to be contacted daily.

The epidemic produced several changes in primary care. GPs were on the front line in this epidemic, but as a consequence of the anti-COVID-19 measures, their activities were suspended with a first, direct effect: chronic care

### Table 2

| Outcome                         | Population not included (G1) | Included but not contacted (G2) | Included and contacted (G3) |
|---------------------------------|------------------------------|-------------------------------|---------------------------|
| Overall mortality, n (%)       | 4125 (0.83)                  | 3065 (3.87)                   | 641 (1.32)                |
| HR* (95% CI)                   | 1.42 (1.33 to 1.51)          | 1.12 (0.99 to 1.26)           | 1.12 (0.99 to 1.26)       |
| OR** (95% CI)                  | 3.73 (3.47 to 4.00)          | 1.09 (0.96 to 1.23)           | 0.30 (0.27–0.34)          |
| COVID-19 morbidity, n (%)      | 3889 (0.79)                  | 1942 (2.46)                   | 335 (0.69)                |
| HR* (95% CI)                   | 2.94 (2.74 to 3.15)          | 2.94 (2.74 to 3.15)           | 2.94 (2.74 to 3.15)       |
| OR** (95% CI)                  | 2.81 (2.62 to 3.01)          | 2.81 (2.62 to 3.01)           | 2.81 (2.62 to 3.01)       |
| COVID-19 hospitalisation, n (%)| 3343 (0.67)                  | 1548 (1.96)                   | 298 (0.61)                |
| HR* (95% CI)                   | 1.2 (1.17 to 1.23)           | 1.14 (1.01 to 1.30)           | 1.14 (1.01 to 1.30)       |
| OR** (95% CI)                  | 1.11 (1.08 to 1.14)          | 1.11 (1.08 to 1.14)           | 1.11 (1.08 to 1.14)       |

* Reference category
was frequently postponed.18 Patient-engaging strategies were developed by GPs via telephone or video consulting. Patient activation, or engaging patients in their own care, has been described as a potential strategy to improve chronic disease self-management.19 20 However, this is conditioned by a pre-existing doctor–patient relationship.

The group followed by the GPs can be considered to have received true multidisciplinary treatment, represented by activation of social services; early evaluation of symptoms; dynamic monitoring of their condition by assessment of new symptom occurrence, changes in current therapy and indications for isolation even from family members; and the use of social distancing and other non-pharmaceutical practices. Only such a diverse range of treatments can explain such a high advantage.

Limitations and strengths
This study has several limitations, and the study design does not allow for causal inferences. Only the use of a randomised design can guarantee protection from confounding and justify causal inferences. However, not only is a randomisation procedure in a pandemic phase unethical, but it would be unacceptable for the population. The possibility of residual confounders cannot be eliminated. Although we controlled for important factors in the data analyses, this provides no guarantee for unbiased results. The definition of an algorithm for selection of the at-risk population, built at the beginning of the epidemic and based on limited data, is a critical issue. Moreover, the causes of death should be investigated in order to better understand how the GP intervention took effect in the high-risk population.

The two groups may differ in severity: table 1 shows a number of differences in terms of prevalence of chronic conditions between included patients. Contacted subjects mostly received concomitant therapies and have a slightly higher prevalence of some chronic diseases. If, indeed, GPs mainly contacted the most severe patients, it means that the potential efficacy of this approach is even greater than that observed.

The major strength of our work is represented by the population-based design including all people aged 70 years or older in the largest Italian metropolitan area, where the COVID-19 pandemic started in Italy.

Conclusion
When managing a pandemic crisis, it is extremely difficult to decide which strategy to adopt. If a government chooses suppression measures, there are substantial social and economic costs that will have long-term effects on the health and well-being of the population. If, however, a mitigation strategy is chosen and regular levels of activity are maintained, the healthcare system risks collapse, with a consequent dramatic increase in the number of deaths. A hypothetical new model could use suppression measures exclusively on compromised/the most vulnerable members of the population in order to control hospitalisation and mortality risk. Stringent measures of social distancing and individual protection could be introduced for the non-compromised population, along with economic and psychological support. This could represent a new overall strategy to protect the high-risk population and also mitigate the social and economic effect of the outbreak.

Innovative, comprehensive strategies need widespread social adhesion/cohesion and strong conviction in order not to create social ghettos, but to instead encourage the population to feel they can join in and help improve life. The possibility of early identification of risk groups that may require a compulsory extended quarantine, aimed at reducing adverse impacts, based on our results, shows promise as a viable path.

It is therefore crucial to foster collaboration among epidemiologists, ethicists, economists and sociologists, so that the social and economic consequences of control strategies are incorporated into the next generation of mathematical models used to guide public health decisions. Finally, it is necessary to reiterate that this intervention, which did not require any economic investment and which leveraged the skills of primary care services integrated with hospitals and the network of GPs, is one of the most successful actions, in terms of health gains, undertaken in public health during the COVID-19 epidemic.
REFERENCES

1. EpiCentro. Sorveglianza integrata COVID-19: I principali dati nazionali. 2020. Available: https://www.epicentro.iss.it/coronavirus/
sars-cov-2-sorveglianza-dati

2. Lazzerini M, Putoto G. COVID-19 in Italy: momentous decisions and many uncertainties. *Lancet Glob Health* 2020;8:e641–2.

3. Sebastiani G, Massa M, Riboli E. Covid-19 epidemic in Italy: evolution, projections and impact of government measures. *Eur J Epidemiol* 2020;35:341–5.

4. Yang P, Qi J, Zhang S, et al. Feasibility study of mitigation and suppression strategies for controlling COVID-19 outbreaks in London and Wuhan. *PLoS One* 2020;15:e0236857.

5. Peng T, Liu X, Ni H, et al. City lockdown and nationwide intensive community screening are effective in controlling the COVID-19 epidemic: analysis based on a modified SIR model. *PLoS One* 2020;15:e0238411.

6. Lau H, Khosrawipour V, Kocbach P, et al. The positive impact of lockdown in Wuhan on containing the COVID-19 outbreak in China. *J Travel Med* 2020;27:taaa037.

7. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* 2020;584:257–61.

8. IATA. COVID-19 government public health mitigation measures, 2021. Available: https://www.iata.org/en/programs/covid-19-
resources-guidelines/covid-gov-mitigation/

9. Thompson RN, Hollingsworth TD, Isham V, et al. Key questions for modelling COVID-19 exit strategies. *Proc Biol Sci* 2020;287:20200540.

10. Stawicki SP, Jeanmonod R, Miller AC, et al. The 2019-2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: a joint American College of academic international Medicine–World academic Council of emergency medicine multidisciplinary COVID-19 Working group consensus paper. *J Glob Infect Dis* 2020;12:47–93.

11. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62.

12. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708–20.

13. Vahidy FS, Nicolas JC, Meeks JR, et al. Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational Registry for a diverse us metropolitan population. *BMJ Open* 2020;10:e039849.

14. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. *JAMA* 2020;323:2052–9.

15. Charlson M, Sztatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. *J Clin Epidemiol* 1994;47:1245–51.

16. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med* 1996;15:361–87.

17. WHO. Country & technical guidance - Coronavirus disease (COVID-19), 2021. Available: https://www.who.int/emergencies/
diseases/novel-coronavirus-2019/technical-guidance

18. Morerell S, Philips H, Verhoeven V. Organisation and characteristics of out-of-hours primary care during a COVID-19 outbreak: a real-time observational study. *PLoS One* 2020;15:e0237629.

19. Blackberry ID, Furler JS, Best JD, et al. Effectiveness of general practice based, practice nurse led telephone coaching on glycaemic control of type 2 diabetes: the patient engagement and coaching for health (peach) pragmatic cluster randomised controlled trial. *BMJ* 2013;347:f5272.

20. Oksman E, Linna M, Hörrhammer I, et al. Cost-Effectiveness analysis for a tele-based health coaching program for chronic disease in primary care. *BMC Health Serv Res* 2017;17:138.